Learn More
BACKGROUND Trastuzumab is widely used as the treatment of choice for HER2-positive metastatic breast cancer (MBC). PATIENTS AND METHODS Seventy patients, median age 57 years and range 31-81 years, were included in our retrospective analysis with the aim to evaluate safety and activity of trastuzumab-containing therapies. RESULTS We observed for(More)
  • 1